BioCorRx Akcie

BioCorRx EV/FCF

EV/FCF (Podniková hodnota k volnému peněžnímu toku) společnosti BioCorRx (BICX) k datu 23. 8. 2026 je -8,78. V předchozím roce byl EV/FCF (Podniková hodnota k volnému peněžnímu toku) -4,70 — změna o 86,62 % (nižší).

EV/FCF

-8,78

YoY

86,62%

Poslední aktualizace:

EV/FCF (Podniková hodnota k volnému peněžnímu toku) společnosti BioCorRx je 2026 -8,78 . EV/FCF (Podniková hodnota k volnému peněžnímu toku) společnosti BioCorRx byl 2025 -4,70 . Klesá tak o 86,62% nižší než v předchozím roce.

Historie BioCorRx EV/FCF

  • 3 roky

  • 10 let

  • 25 Let

  • Maximum

EV/FCF
Date
EV/FCF
1. 1. 2017
-3,66 USD
1. 1. 2018
-5,92 USD
1. 1. 2019
-1,56 USD
1. 1. 2020
-3,21 USD
1. 1. 2021
-2,29 USD
1. 1. 2022
-4,12 USD
1. 1. 2023
-4,70 USD
1. 1. 2024
-8,78 USD
Historie BioCorRx EV/FCF
ROKEV/FCFYoY
-8,78+86,62%
-4,70+14,31%
-4,12+79,40%
-2,29-28,45%
-3,21+105,88%
-1,56-73,69%
-5,92+61,72%
-3,66+3,85%
-3,52-102,04%
172,91+280,98%
45,39
Access this data via the Eulerpool API

BioCorRx Analýza akcií

Co dělá BioCorRx? The company BioCorRx Inc is a US-American company that was founded in 2008 and is headquartered in Anaheim, California. BioCorRx specializes in the development and marketing of innovative treatment methods for alcohol and drug dependency. The history of BioCorRx began with the introduction of its flagship product, the BioCorRx Recovery Program, which is based on a novel medical technology called Naltrexone/Buprenorphine Implant. Unlike traditional methods of treating alcohol and drug addiction, which typically rely on medication and psychotherapeutic support, the BioCorRx Recovery Program is an implantable, long-term treatment system that continuously delivers the active ingredient Naltrexone or Buprenorphine into the patient's body. The idea behind this is that the active ingredients prevent withdrawal symptoms and thereby reduce the risk of relapse. In recent years, BioCorRx has expanded its product portfolio and expanded its business activities to new segments in order to further drive the company's growth. This includes, for example, the field of telemedicine services, which allow BioCorRx to offer its treatment technology and medical services through online communication. Telemedicine services such as virtual patient consultation or online group therapy programs are particularly in demand in times of COVID-19. Another focus of BioCorRx is the management of medical personnel. Studies have shown that good patient care and counseling heavily influence the success of treatment. BioCorRx has now also developed its own platform that eases and improves the management, training, and monitoring of medical staff. BioCorRx also utilizes the concept of franchise systems to market its products and services. The franchise system offers medical professionals and organizations working in the field of addiction treatment the opportunity to open their own BioCorRx clinic and offer the company's products and services in their local market. Each clinic is advised and supported by BioCorRx and must adhere to certain standards and quality criteria. In the future, BioCorRx plans to further diversify its product offering and develop new technologies to improve treatment options for alcohol and drug dependents. An example of such a technology is medication based on Ibogaine. BioCorRx has already started initial research in this direction and is actively working on pre-clinical studies. Overall, BioCorRx is a company that primarily focuses on innovative technologies for the treatment of addiction. The company has experienced substantial growth in recent years by expanding its product range and customer base, and focusing on the areas of telemedicine, personnel management, and franchise systems. With its forward-thinking technologies and strong emphasis on quality and patient satisfaction, BioCorRx is expected to continue playing an important role in addiction treatment in the years to come. BioCorRx je jednou z nejoblíbenějších společností na Eulerpool.com.

Často kladené otázky ohledně akcií BioCorRx

EV/FCF (Podniková hodnota k volnému peněžnímu toku) společnosti BioCorRx činí -8,78 v roce 2026.

EV/FCF (Podniková hodnota k volnému peněžnímu toku) společnosti BioCorRx se změnilo z -4,70 na -8,78, což představuje změnu o 86,62 %. Hodnota je nižší než v předchozím roce.

Na Eulerpool najdete úplný historický vývoj EV/FCF (Podniková hodnota k volnému peněžnímu toku) BioCorRx od roku 2006 – s ročními hodnotami, grafy a podrobnou analýzou.

Poměr EV/FCF měří podnikovou hodnotu vůči volnému peněžnímu toku a zachycuje skutečnou schopnost podniku generovat peníze.

Srovnávejte ukazatele s průměry odvětví, protože se normy výrazně liší. Například marže maloobchodu jsou obecně nižší než marže softwaru.

Dobrá hodnota se liší podle odvětví a fáze vývoje společnosti. Na Eulerpool můžete porovnat BioCorRx společnosti EV/FCF (Podniková hodnota k volnému peněžnímu toku) s porovnatelnými společnostmi a průměrem odvětví, abyste určili, zda je atraktivní.

Access this data via the Eulerpool API

Oceňování — BioCorRx

Všechny klíčové ukazatele — BioCorRx